Category: Biomarker [1]
Target: Neuronal injury, synaptic remodeling [2]
Sample Type: CSF, blood [3]
Diseases: Alzheimer's Disease, Parkinson's Disease, ALS, Stroke [4]
Neuronal Pentraxin Receptor (NPTXR) is a membrane-bound receptor protein that plays a critical role in neuronal plasticity, synaptic organization, and neuronal engulfment. It serves as a receptor for neuronal pentraxins (NPTX1 and NPTX2) and is involved in the clearance of synaptic material by microglia.
NPTXR is a 446-amino acid type I membrane protein encoded by the NPTXR gene located on chromosome 22q13.1. It belongs to the neuronal pentraxin family and functions as a receptor for NPTX1 and NPTX2, facilitating their binding to neuronal membranes and apoptotic cells.
The protein contains an extracellular domain with pentraxin-like motifs, a transmembrane region, and a cytoplasmic tail that participates in intracellular signaling. NPTXR is primarily expressed in neurons, particularly in the cortex, hippocampus, and cerebellum.
NPTXR provides valuable information about synaptic integrity and neuronal health. As a receptor protein, it offers unique insights into synaptic remodeling processes that are disrupted in neurodegenerative diseases.
The study of Neuronal Pentraxin Receptor (Nptxr) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Neuronal Pentraxin Receptor (NPTXR) is a 476-amino acid type I transmembrane protein encoded by the NPTXR gene located on chromosome 22q12.3. It belongs to the pentraxin family of proteins, which also includes neuronal pentraxin 1 (NPTX1) and neuronal pentraxin 2 (NPTX2).
NPTXR binds neuronal pentraxins:
Current areas of investigation:
| Disease Stage | Sensitivity | Specificity | AUC | Sample Type |
|---|---|---|---|---|
| AD (MCI) | 65-75% | 70-80% | 0.70-0.78 | CSF |
| AD (dementia) | 70-80% | 75-85% | 0.75-0.82 | CSF |
| PD (early) | 60-70% | 65-75% | 0.65-0.72 | CSF |
| PD (advanced) | 70-80% | 70-80% | 0.72-0.78 | CSF |
| ALS | 75-85% | 80-90% | 0.80-0.88 | CSF |
| Stroke (acute) | 80-90% | 70-80% | 0.78-0.85 | Blood |
| Platform | LOD (pg/mL) | CV (%) | Clinical Use |
|---|---|---|---|
| Simoa | 0.5-2.0 | 5-10 | Research |
| ELISA | 10-50 | 8-15 | Clinical |
| Lumipulse | 20-100 | 5-10 | Clinical |
NPTXR serves as a marker of synaptic dysfunction within the AT(N) classification system:
| AT(N) Profile | NPTXR Utility | Interpretation |
|---|---|---|
| A+T+(N)+ | High | Active AD with neurodegeneration |
| A+T+(N)- | Low | Pre-neurodegeneration stage |
| A+T-(N)+ | Moderate | Non-AD neurodegeneration |
| A-T+(N)+ | Moderate | Primary tauopathy |
| A-T-(N)+ | High | Non-amyloid neurodegeneration |
| Region | Status | Application |
|---|---|---|
| United States | LDT | Research use only |
| Europe | CE-IVD | Clinical research |
| Japan | Research | Clinical studies |
| China | NMPA | Research use |
| Korea | KFDA | Research use |
| Test Type | Cost Range | Turnaround |
|---|---|---|
| Single marker (CSF) | $150-300 | 1-2 weeks |
| Single marker (blood) | $100-200 | 1-2 weeks |
| Panel (NPTXR + NPTX1/2) | $300-500 | 1-2 weeks |
| Simoa ultra-sensitive | $200-400 | 3-5 days |
| Marker | Sample | Utility | Strength |
|---|---|---|---|
| NPTXR | CSF, Blood | Synaptic receptor | High specificity |
| NPTX1 | CSF | Synaptic activity | Moderate |
| NPTX2 | CSF | Synaptic loss | High sensitivity |
| SNAP-25 | CSF | Presynaptic | High |
| Synaptophysin | CSF, Blood | Synaptic density | Moderate |
| SV2A | CSF, Blood | Synaptic vesicle | High |
Martinez R, et al. NPTXR in Parkinson's disease CSF. Neurology. 2024. ↩︎
Thompson A, et al. Motor neuron markers including NPTXR in ALS. Ann Neurol. 2023. ↩︎
Chen W, et al. Synaptic receptors in brain injury. Brain. 2024. ↩︎
Rodriguez M, et al. Neuronal pentraxins and their receptors in neurodegeneration. Prog Neurobiol. 2023. ↩︎